Patient burden as an operational metric of clinical trial success
Patient advocate Christine Von Raesfeld says patient burden should join trial metrics such as cost and regulatory compliance....
Patient advocate Christine Von Raesfeld says patient burden should join trial metrics such as cost and regulatory compliance....
Clinical trials often face low accrual and retention, and involving communities in their planning and conduct is crucial to build public trust and rectify this issue....
This article explores the evolution of ethical standards in clinical research, emphasizing historical violations and contemporary challenges....
Clinical research has a talent problem, and the future of this industry depends on how we respond. It’s not just about recruitment or retention....
Clinical trials are a crucial step in medical research, and without adequate numbers of participants, treatments can be delayed or prevented from reaching the health care market. ...
Long-standing concerns over if, when, and how to compensate clinical trial participants for the time and effort they put into studies are akin to a “Which came first, the chicken or the egg?” dilemma for many research practitioners. ...
The erosion of trust will devastate drug trial recruitment....
A recent study of 978 cancer patients and their relatives uncovered reasons behind their willingness, or lack thereof, to participate in clinical research....
Children and teenagers bring unique value to research as advisers and participants — raising ethical and practical issues about how best to compensate them....
Diversity action plans—focused on enrolling representative numbers of participants in clinical trials from historically underrepresented racial and ethnic populations—are part of U.S. Food and Drug Administration (FDA) draft guidance published in April 2022....